Trial · NCT06825013
Bronchodilators and Lung Mechanics During Exercise in COPD
NCT06825013, Phase 4, Recruiting, Dr. J. Alberto Neder
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bronchodilators and Lung Mechanics During Exercise in COPD. Trials, record NCT06825013. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06825013
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bronchodilators and Lung Mechanics During Exercise in COPD
- NCT number
- NCT06825013
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Dr. J. Alberto Neder
- Conditions
- COPD
- Interventions
- Bronchodilators inhalation, Placebo
- First posted
- 2025-02-13
- Last updated
- 2025-02-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Airway resistance | At 2, 4, 6, 8, and 10 minutes from start of exercise | Primary objective is to measure airway resistance measured by impulse oscillometry at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Inspiratory neural drive | At 2, 4, 6, 8, and 10 minutes from start of exercise | Secondary objective is to measure inspiratory neural drive (IND) by diaphragm activation (EMGdi%max) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Esophageal Pressure (Pes) | At 2, 4, 6, 8, and 10 minutes from start of exercise | Secondary objective is to measure esophageal pressure (Pes) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Gastric Pressure (Pga) | At 2, 4, 6, 8, and 10 minutes from start of exercise | Secondary objective is to measure gastric pressure (Pga) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Trans-diaphragmatic Pressure (Pdi) | At 2, 4, 6, 8, and 10 minutes from start of exercise | Secondary objective is to measure trans-diaphragmatic pressure (Pdi) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Operating lung volumes | At 2, 4, 6, 8, and 10 minutes from start of exercise | Secondary objective is to measure inspiratory capacity at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Exertional dyspnea | At 2, 4, 6, 8, and 10 minutes from start of exercise | Primary objective is to measure perceptual (e.g. intensity of dyspnea) responses at isotime (maximum exercise time achieved by all participants) during a standardized cardiopulmonary exercise testing (cycle ergometer). |
| Secondary | Exercise tolerance | Within 10-12 min from start of cardiopulmonary exercise test | Exercise tolerance will be assessed as the time from start of loaded pedaling to end of loaded exercise. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06825013
GET https://conductscience.org/api/trials/v1/NCT06825013/registered